Phase I trial of 2-methoxyestradiol NanoCrystal dispersion in advanced solid malignancies (Q33942951)

30 July 2017

title

Phase I trial of 2-methoxyestradiol NanoCrystal dispersion in advanced solid malignancies (English)

1 reference

30 July 2017

main subject

phase I clinical trial

0 references

2-methoxyestradiol

1 reference

ChEBI release 2020-05-28

1 reference

7

George Wilding

1 reference

30 July 2017

Amye J Tevaarwerk

1

1 reference

30 July 2017

Kyle D Holen

2

1 reference

30 July 2017

Dona B Alberti

3

1 reference

30 July 2017

Carolyn Sidor

4

1 reference

30 July 2017

Jamie Arnott

5

1 reference

30 July 2017

Check Quon

6

1 reference

30 July 2017

Glenn Liu

8

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 February 2009

1 reference

30 July 2017

published in

Clinical Cancer Research

1 reference

30 July 2017

volume

15

1 reference

30 July 2017

issue

4

1 reference

30 July 2017

page(s)

1460-1465

1 reference

Mechanism of action of 2-methoxyestradiol: new developments

30 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892631

2-methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892631

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892631

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892631

The antiangiogenic agents TNP-470 and 2-methoxyestradiol inhibit the growth of angiosarcoma in mice

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892631

2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: possible role for stress-activated protein kinase signaling pathway and Fas expression.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892631

The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892631

Serum concentration and urinary excretion of “classical” estrogens, catecholestrogens and 2-methoxyestrogens in normal human pregnancy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892631

Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892631

Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892631

Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892631

A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892631

2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892631

Potent antitumor activity of 2-methoxyestradiol in human pancreatic cancer cell lines.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892631

Panoparticulate systems for improved drug delivery

29 October 2018

1 reference

12 December 2020

2-Methoxyestradiol Arrests Cells in Mitosis without Depolymerizing Tubulin

1 reference

12 December 2020

Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs

1 reference

12 December 2020

Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol

1 reference

12 December 2020

Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer

1 reference

12 December 2020

Characterization of in vitro and in vivo metabolic pathways of the investigational anticancer agent, 2-methoxyestradiol

1 reference

12 December 2020

10.1158/1078-0432.CCR-08-1599

Identifiers

DOI

1 reference

30 July 2017

1 reference

30 July 2017

1 reference